In the original version of this article (1), the stated disclosure of José Baselga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.
References
1.
Juric
D
, Krop
I
, Ramanathan
RK
, Wilson
TR
, Ware
JA
, Sanabria Bohorquez
SM
, et al Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors
. Cancer Discov
2017
;7
:704
–15
.©2018 American Association for Cancer Research.
2018
American Association for Cancer Research.
RSS Feeds